Long Ideas - With the stock down 20% in early morning trading on Friday, October 11, PropThink wrote to PropThink Premium subscribers that Endocyte’s (ECYT) weakness offered another buying opportunity … Continue Reading
Read NowMost Popular - At PropThink, the story of the day on Friday was the sell-off in Endocyte, Inc (ECYT). Endocyte‘s lead asset is vintafolide, a folate receptor-targeting small … Continue Reading
Read NowMost Popular - Our open conference call with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray on Thursday afternoon was a success on a number of fronts – participation, … Continue Reading
Read NowLong Ideas - On October 3, 2013, PropThink hosted an interview and investor Q&A with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray. A recording and transcript of that … Continue Reading
Read NowMost Popular - It seems Vivus Pharmaceuticals (VVUS) may have some important news coming. Two Vivus patent applications covering Qsymia appear to be in a condition for allowance … Continue Reading
Read NowLong Ideas - On Tuesday afternoon at 2:30PM ET, Progenics (PGNX) and Salix Pharmaceuticals (SLXP) announced that an FDA advisory committee weighing the Supplemental New Drug Application for … Continue Reading
Read NowMost Popular - For those that missed our press release on Friday, PropThink will be hosting a live interview and Q&A with Dr. Mark Murray, CEO of Tekmira Pharmaceuticals (TKMR) (TKM.TO) on Thursday, October 3 … Continue Reading
Read Now